Cellartis

company

About

Cellartis develops human embryonic stem cells and technology for drug discovery research, toxicity testing and regenerative medicine.

  • 51 - 100

Details

Last Funding Type
Series Unknown
Last Funding Money Raised
€8M
Industries
Biotechnology
Founded date
Jan 1, 2001
Number Of Employee
51 - 100
Operating Status
Active

Cellartis AB is a Swedish/British biotechnology company focused on pluripotent stem cells and technology for drug discovery research, toxicity testing and regenerative medicine

Since 2001, Cellartis has worked globally with industry and academia, platform providers and end users to develop the next generation of advanced stem cell products and technologies. The company leverages a deep experience in stem cell handling, scale up and differentiation into mature and functional human cells. The company was first in the world to bring to the market human embryonic stem (hES) cell-derived hepatocytes and cardiomyocytes for use as drug discovery tools today.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
€8M
Cellartis has raised a total of €8M in funding over 2 rounds. Their latest funding was raised on Dec 13, 2005 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 13, 2005 Series Unknown €8M 2 Detail

Investors

Number of Lead Investors
Number of Investors
2
Cellartis is funded by 2 investors. Catella Healthcare Investments and T-bolaget are the most recent investors.
Investor Name Lead Investor Funding Round
Catella Healthcare Investments Series Unknown
T-bolaget Series Unknown